Curis Announces FDA Fast Track Designation for Fimepinostat Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

LEXINGTON, Mass., May 31, 2018 -- (Healthcare Sales & Marketing Network) -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, announced today that t... Biopharmaceuticals, Oncology, FDA Curis, fimepinostat, lymphoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news